Contents lists available at UGC-CARE

International Journal of Pharmaceutical Sciences and Drug Research

[ISSN: 0975-248X; CODEN (USA): IJPSPP]

Available online at www.ijpsdronline.com

Research Article

# Formulation Development and Evaluation of Site Specific Periodontal Fibers of Metronidazole and Minocycline HCl

**Kokkilagadda V. Kumar[1,2*], Reddyvalam L. C. Sasidhar[3], Bandarupalli Deepthi[4]**

[1]*Acharya Nagarjuna University, Nagarjuna Nagar, Guntur-522510, Andhra Pradesh, India*
[2]*SIMS College of Pharmacy, Mangaldas Nagar, Guntur-522509, Andhra Pradesh, India*
[3]*Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur-522019, Andhra Pradesh, India*
[4]*Siddhartha Institute of Pharmaceutical Sciences, Narasaraopet- 522601, Andhra Pradesh, India*

ARTICLE INFO

**Article history:**
Received: 09 June, 2021
Revised: 12 October, 2021
Accepted: 20 October, 2021
Published: 30 November, 2021

**Keywords:**
Fibers,
HCl,
Metronidazole,
Minocycline,
Periodontal pockets,
Periodontitis.

**DOI:**
10.25004/IJPSDR.2021.130606

ABSTRACT

Periodontal disease is a collective term for a variety of pathological conditions characterized by relapse and inflammation of the gums, periodontal sinews, alveolar bone, and dental cementum. It is a confined inflammatory reaction caused by bacterial infection of a periodontal pocket in conjunction with subgingival plaque. Even though bacteria are the primary cause of periodontal disease, the presence of microbial pathogenic aspects may not be required to cause periodontitis. Periodontal pathogens produce harmful byproducts and enzymes that disrupt extracellular matrices as well as host cell membranes in order to produce nutrients for their growth. A number of antimicrobial products are summarized, as well as the composition of the delivery systems, their use, clinical results, and release. The goal of using an intra-pocket device for antimicrobial agent delivery is to achieve and maintain therapeutic drug concentration for the desired period of time. With precise control of the rate at which a specific drug dosage is released from a delivery system without the need for frequent administration, novel controlled drug delivery systems are capable of improving patient compliance as well as therapeutic efficacy. Because of their low cost, greater stability, non-toxicity, biocompatibility, non-immunogenicity, and biodegradability, these are considered superior drug delivery systems. In this study, a site-specific periodontal drug delivery system for Metronidazole and Minocycline HCl was developed. The augmented fibre formulation G-II laterally with scaling and root planning was effective in eliminating local irritants, reducing gingival inflammation, reducing pocket depth, and increasing clinical addition. Method (A) revealed a determined drug release of 81.8 percent over a period of 120 hours, while method (B) released 84 percent drug(s) over a period of 264 hours. For the optimized formulation, the value of n is assumed to be 0.9314 and follows zero-order. It also measured the restricted infection and prevented the formation of new lesions. In the current revision, there was a significant decrease in mean plaque index, gingival index, sulcus bleeding index, and probing pocket depth, as well as a significant increase in clinical affection. The current study's local drug delivery system is artless and simple to use.

## Introduction

The periodontal pocket affords ideal environments for the proliferation of microorganisms, mostly Gram negative, facultative anaerobic species. Blatantly these are Bacteroides spp.: *Bacteroides intermedius* and *Bacteroides gingivalis*; fusiform organisms: *Actinobacillus actinomycetemcomitans*, *Wolinella recta* and Eikenella spp.; and various *bacilli* and *cocci*; *spirochetes*; *amoebas* and *trichomonads*. The periodontal pocket, nevertheless, ruins and if it endures to harbor the bacteria allied with the disease, a probable for an added destructive phase exists. The disease may then necessitate widespread treatment, worsening which the teeth may be lost.[1] It is for this reason that periodontitis patients prioritise clearing up the subgingival infection and cleaning out their periodontal pockets. Periodontitis therapy frequently includes a full

***Corresponding Author:** Kokkilagadda V. Kumar

Address: Acharya Nagarjuna University, Nagarjuna Nagar, Guntur-522510, Andhra Pradesh, India, Associate Professor, SIMS College of Pharmacy,

**Email** ✉**:** kvinodkumar8@gmail.com

**Relevant conflicts of interest/financial disclosures:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

antibiotic schedule to alter the likely pathogenic flora. Additionally, some tetracyclines appear to reduce bone loss by inhibiting collagenase. Surgical excision of the pocket and raconteur of the bone can encourage alveolar bone advancement as an alternative strategy. A new study examined the impact of experimentally injured rat perialveolar bone on the regenerative process of the synthetic flavonoid plagiaristic, ipriflavone. Post-menopausal and elderly osteoporosis is a common problem for this group, thus they take oral medications to treat it. To increase medicine concentration immediately at the site of action while also limiting systemic side effects such gastrointestinal symptoms, depression, and tachycardia, local solicitation into the periodontal pocket may be quite beneficial. Toothpaste and mouthwash conformist medication compositions have relatively limited periodontal pocket dispersion.[2,3]

Fibers are used for the management of periodontitis. They can be classified into two types,

- Hollow fiber
- Monolithic fiber

Hollow fibers contain reservoirs devoid of rate-controlled delivery and bursting with medicinal substance. The medicinal drug is unhindered in these only by clinched reservoir wall diffusion. Goodson first delivered the hollow fiber with attractive cellulose acetate toned fibers occupied with tetracycline using expedients. While in the periodontal pocket, these fibers helped reduce the amount of bacteria and the severity of symptoms patients were experiencing. Nevertheless the hollow fiber system unconstrained the drug very swiftly and was not precise efficacious at nourishing the drug release.[4]

Monolithic fibers were principally advanced to retard drug release. Monolithic fibers were made of ethylene vinyl acetate loaded with 25% tetracycline hydrochloride were positioned to fill the periodontal pocket of 10 patients, which was protected with a periodontal dressing. The ordinary concentration of tetracycline in pocket after 10 days was 643 ug/mL and the total count of pocket microflora was miserable to a level near the limit of dark field microscopy.[5] In the belongings reachable, tetracycline fiber was engaged as a supplement to mechanical analysis and oral hygiene in a miscellany of clinical position. Endings embraced depression of periodontal pathogens, diminishing of bleeding on probing, decline in probing pocket depths and escalation in probing addition level. Tetracycline fiber management adjunctive to SRP unveiled alluringly less periodontal disease repetition (4%) equaled with SRP alone (9%), tetracycline fiber unaided for 10 days (10%) and tetracycline fiber only for 20 days (12%). Revisions that were well steered and well controlled have verified the clinical efficiency of these fibers but their genuine value in patient therapy has been marginally trying to interpret because clinicians have initiated the fiber engagement technique exciting. A reading indicated that patients practiced discomfort through fiber appointment and at fiber confiscation innumerable degrees of gingival redness were pragmatic.[6] The intricacies of winding a fiber into place, the prerequisite to preserve the device inside the pocket and then the confiscation of it after seven to ten days may limit its wide receiving by patients and periodontitis.

## Materials and Methods

### Materials

Metronidazole (MTZ) was obtained as a gift sample from Sanctus Drugs & Pharmaceuticals Pvt. Ltd. Hyderabad, Minocycline hydrochloride (MHCl) gift sample from SR Finechem India Pvt Ltd Hyderabad, Hydroxy ethyl cellulose (HEC), Methylcellulose (MC) and poloxamer 407 were obtained from SD Fine-Chemicals Ltd, Mumbai.

### Drug(s) Identification Tests[7]

#### *Melting Point Determination*

Melting point of Metronidazole and Minocycline HCl was determined by capillary fusion method.

#### *UV Spectrophotometric Study*

MTZ powder 10 mg was accurately weighed and transferred to 100 mL volumetric flask. It was dissolved and diluted to 100 mL with 0.l-mL HCl solution to obtain a final concentration of 100 μg/mL. 3.5 mL of the above solution was pipette out and diluted to 10 mL to obtain a final concentration of 35 μg/mL and scanned in the range 200–400 nm in basic spectrum model. Similarly standard solution of MTZ was scanned in phosphate buffer.

MHCl powder 10 mg was accurately weighed and transferred to 100 mL volumetric flask. It was dissolved and diluted to 100 mL with phosphate buffer pH 7.4 solution to obtain a final concentration of l00 μg/mL. 3.5 mL of above solution was pipette out and diluted to 10 mL to obtain a final concentration of 35 μg/mL and scanned in the range 200–400 nm in basic spectrum mode1 50. In a similar manner the scan was made in double distilled water.

### Drug(s) Excipient Compatibility Studies[8]

#### *Physical State*

For this study, drug(s) and excipients were taken in ratio similar to that to be taken in formulation. Water was added in a quantity of 0.45% w/v as a worst case. The mixtures prepared were placed in vials, sealed and stored in an oven at a temperature of 50 ± l°C for two weeks. At the end of two weeks the mixtures were observed for their physical state i.e. (discoloration, caking and liquefaction) and analyzed by TLC.

#### *FT-IR Spectroscopy*

The desired quantities of drug with specified excipient(s) (1:1 and 1:5) were granulated. Sieved with # 22 (mesh), dried in air, filled and sealed in dried glass vials and stored at 55°C for 2 weeks. Examined periodically each day it for discoloration, caking, liquefaction.

Drug excipient compatibility studies were carried out using diffuse reflectance spectroscopy (DRS). In this technique solid drug, excipient(s) and their physical mixtures were diluted with KBr (IR grade) to get the samples for measurement in the transmittance mode (%T). The diffuse reflectance spectrum of the samples against the diluting material was measured by setting the accumulation times to approximate 50. The spectra obtained were evaluated for any incompatibility.[9]

## Preparation of Drug(S) Loaded Fibers

The drug(s) loaded fibers were organized by coating technique. In order to coat exciting amount of drug(s) on fibers, polymer and drug(s) solutions were ordered in ethanol and were mixed in unrelated ratios (3:2, 1:1, 2:3 and 4:1). The fibers were coated five times. After each coating, the fibre was assessed to legalize the drug(s) load. Amount of drug(s) loaded was ancillary inveterate by shaking the fibre in ethanol and the resulting solution was filtered and analyzed spectrophotometrically by subtracting the absorbance at 319 and 273.8 nm and actual concentration of drug(s) was extrapolated from calibration curve of MTZ and MHCl organized at 319 and 273.8 nm. Fibers were coated by the two subsequent methods.[10]

### *1) Using Dilute Solution of Drug(S) (Method A)*

Using ethanol as solvent, a 20% w/v solution of polymer was organized. Drug(s) solution was planned to give a concentration of 3 mg/mL. Polymer solution and drug(s) solutions were assorted exactly on weight basis. Fibers (10 cm long) were pondered and curved in coating solution for about 5 mm and kept as such and dried at 45°C for half a hour. The weight of the coated fibre was taken and the amount of drug(s) coated on it was expected on a weight basis.[11]

The drug(s) loading was also untiring spectrophotometrically at 319 and 273.8 nm. Coating was done five times and each time, the satisfied of drug(s) extant in the coating was feasible. The amount of drug(s) in coated fibers with varied number of coatings is unoccupied is publicized in Table 1.

### *2) Using Concentrated Solution of Drug(S) (Method B)*

In this practice, concentrated solutions of drug(s) were organized by dissolving 50 mg and 100 mg drug(s) in 5 mL of ethanol, ensuing in concentrations of 10 and 20 mg/mL respective1y.[12] Rest of the practice was same as conferred in section (A). The expanse of drug(s) in coated fibers with dissimilar number of coatings is presented in Table 2.

## *In-vitro* Release of Drug(S) From Coated Fibers

Release of MTZ and MHCl from the fibre was determined by submersing the illustration in a ampoule filled with 50 mL of isotonic phosphate buffer devouring pH 6.6 and encircling 2.25% glycoproteins. The bottle was impenetrable and then incubated at 37°C in a shaking water bath (Veego, Mumbai). Three-mL of sample was solitary, filtered and analyzed for drug(s) content at 319 nm and 273.8 nm. Same volume of fresh dissolution media was supplanted. The expanse of drug(s) released was untiring at different time intervals.[13]

Dissolution data was analyzed using the equality anticipated by Ritger and Peppas to entitle the drug(s) release of the drug(s) from the matrix: $M_t/M_\omega = Ktn$, where $M_t$ parallels to the amount of drug(s) released in time t, $M_\omega$ is the total amount of drug(s) released after inestimable time, K symbolizes a constant and n is the release supporter representing the type of drug(s) release mechanism.[14] Different kinetic equations (zero order, first order and

**Table 1:** Amount of loaded drug(s) in fibers coated by solution technique
**(Ref:** Method A) (± S.D.)

| *Set No.* | *Coating composition(g)* | *Average content of drug(s) in fiber (mg) n=3(+S.D.)* | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | *P=6* | *A-I* | | *A-II* | | *A-III* | | *A-IV* | | *A-V* | |
| A | D=4 | (MTZ) 0.34 (0.012) | (MHCl) 0.41 (0.098) | (MTZ) 0.58 (0.012) | (MHCl) 0.61 (0.087) | (MTZ) 0.68 (0.044) | (MHCl) 0.71 (0.047) | (MTZ) 0.917 (0.020) | (MHCl) 0.897 (0.028) | (MTZ) 1.54 (0.065) | (MHCl) 1.75 (0.069) |
| B | P=5 | B-I | | B-II | | B-III | | B-IV | | B-V | |
| | D=5 | (MTZ) 0.19 (0.016) | (MHCl) 0.20 (0.018) | (MTZ) 0.345 (0.004) | (MHCl) 0.457 (0.007) | (MTZ) 0.622 (0.009) | (MHCl) 0.669 (0.006) | (MTZ) 0.7 (0.024) | (MHCl) 0.9 (0.078) | (MTZ) 1.04 (0.065) | (MHCl) 2.09 (0.089) |
| C | P=4 | C-I | | C-II | | C-III | | C-IV | | C-V | |
| | D=6 | (MTZ) 0.09 (0.001) | (MHCl) 0.09 (0.001) | (MTZ) 0.105 (0.004) | (MHCl) 0.105 (0.004) | (MTZ) 0.288 (0.001) | (MHCl) 0.342 (0.007) | (MTZ) 0.534 (0.012) | (MHCl) 0.675 (0.0876) | (MTZ) 0.98 (0.02) | (MHCl) 0.99 (0.04) |
| D | P=8 | D-I | | D-II | | D-III | | D-IV | | D-V | |
| | D=2 | (MTZ) 0.06 (0.001) | (MHCl) 0.08 (0.003) | (MTZ) 0.10 (0.001) | (MHCl) 0.12 (0.002) | (MTZ) 0.172 (0.016) | (MHCl) 0.167 (0.023) | (MTZ) 0.24 (0.012) | (MHCl) 0.27 (0.014) | (MTZ) 0.328 (0.004) | (MHCl) 0.376 (0.008) |

**Table 2:** Amount of loaded drug(S) in fibers coated by concentrated drug(S) solution technique (Ref: Method B) (± S.D.)

| *Set No.* | *Coating composition(g)* | *Average content of drug(s) in fiber (mg) n=3(+S.D.)* | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | *P=6* | *A-II* | | *A-III* | | *A-IV* | | *A-V* | |
| E | D=4 | (MTZ) 0.53 (0.012) | (MHCl) 0.65 (0.098) | (MTZ) 0.65 (0.044) | (MHCl) 0.68 (0.044) | (MTZ) 0.92 (0.001) | (MHCl) 0.98 (0.009) | (MTZ) 1.41 (0.040) | (MHCl) 1.47 (0.078) |
| F | P=5 | B-II | | B-III | | B-IV | | B-V | |
| | D=5 | (MTZ) 0.62 (0.014) | (MHCl) 0.68 (0.065) | (MTZ) 0.84 (0.016) | (MHCl) 0.91 (0.076) | (MTZ) 1.17 (0.014) | (MHCl) 1.98 (0.074) | (MTZ) 2.08 (0.069) | (MHCl) 3.87 (0.088) |
| G | P=4 | C-II | | C-III | | C-IV | | C-V | |
| | D=6 | (MTZ) 1.0 (0.081) | (MHCl) 1.17 (0.087) | (MTZ) 1.46 (0.05) | (MHCl) 2.65 (0.07) | (MTZ) 1.98 (0.024) | (MHCl) 2.47 (0.064) | (MTZ) 2.83 (0.044) | (MHCl) 3.98 (0.048) |
| H | P=8 | D-II | | D-III | | D-IV | | D-V | |
| | D=2 | (MTZ) 1.03 (0.016) | (MHCl) 1.76 (0.076) | (MTZ) 1.6 (0.016) | (MHCl) 2.7 (0.055) | (MTZ) 2.14 (0.069) | (MHCl) 2.76 (0.087) | (MTZ) 2.81 (0.081) | (MHCl) 2.98 (0.061) |

Higuchi equation) were genuine to interpret the release rates of drug(s) from the fibre at pH 6.6.

## Optimization of the Formulation

The formulation was accustomed on the origin of percent drug(s) release terminated an epoch of time. Formulation A-II ('A' postulates the coating alignment encircling polymer solution and drug(s) solution, i.e., 6 and 4 g individually; and II signposts two coatings agreed to the fibers), organized by solution technique (Method (A)), unveiled extreme drug(s) release of 81.8% over a passé of 120 hours; whereas formulation F-II requires coating composition encircling 5 g of drug(s) solution (content of drug(s) 100 mg) and 5 g of polymer solution and II stipulates two coatings given to the fibers, organized by method (B), released 84% drug(s) over a period of 264 hours (11 days). On the origin of percent drug(s) release concluded for a period, it was resolute that F-II was the optimized formulation. The optimized fibre of MTZ and MHCl (F-II) was assessed for universal appearance. The color of the formulation was white with an identical trivial bitter taste. The fiber was slightly flexible in consistency with a diameter of 0.6 mm and length of 10 cm.

## Microbiological Evaluation of *In-situ* Release Samples

The nutrient agar media and blood agar media were structured by standard processes. Sterilized Petri dishes were engaged, and 25 mL of media was emptied into Petri dishes aseptically and legitimate to congeal. Before solidification, it was jabbed with nearby 0.2 mL culture of microbes (0.5 McFarland standards) employed in such infections. Nutrient agar was inoculated with *E. coil* and *S. aureus*, whereas blood agar media was inoculated with *S. mutans* and *B. cereus*. The samples accomplished from in situ release studies were filtered through sterilized Millipore membrane filters (0.2 μ) and added in cups bored in inoculated solidified media. These were incubated at 37°C for a period of 48 hours in an incubator. The diameter of the zone of inhibition was illustrious. The same practice was ratified for placebo formulation.[15]

## Permeation Studies on the Optimized Fiber across Buccal Membrane

An amended description of Franz diffusion cell was used to revision the permeation of drug(s) bovine mucosal membrane; to realize this; isotonic phosphate buffer of pH 7.4 (the physiological pH of plasma) was engaged in the receiver compartment. The muster embraced of two chambers. The upper cylindrical chamber, which was from exceeding, harbored the bovine buccal mucosa at the base and the fiber was placed on top of it. The lower chamber was in the form of a closed cylinder encircling a ling port and had Teflon-coated magnetic needle at the base. The junction among two spaces was compactly dwindling by placing buccal mucosa in amid the two chambers.[16] Fifteen milliliters of isotonic phosphate buffer of pH 7.4 was supplementary to the lower chamber encircling Teflon-coated needle. Upper chamber demarcated 10 mL of isotonic phosphate buffer of pH 6.6. The cell was positioned on a magnetic stirrer. The whole outfit was kept at 37°C in an oven. Three-mL sample was introverted at diverse time intervals over a period of 11 days from the lower chamber.[17] The samples were filtered, diluted applicably and were analyzed spectrophotometrically at 319 and 273.8 nm for the quantity of drug(s) permeated.

## Results and Discussion

### Drug(s) Identification Tests

#### *Melting Point Determination*

The results of the pharmacopoeial drug(s) identification tests for MTZ and MHCl are tabulated in Table 3. The results confirm the identity and purity of both the API'S.

#### *UV Spectrophotometric Study*

First process schedules the formation and solving of simultaneous equation using 319 nm and 273.8 nm as two analytical wavelengths for both drugs in phosphate buffer of pH 7.4. The second process is Q-value exploration based on extent of absorptivity at 319 and 291.6 nm (as an iso-absorptive point). The overlay spectra of MTZ and MHCl exhibits $\lambda_{max}$ of 319 nm and 273.8 nm individually which are alienated from each other. Furthermore, two iso-absorptive points were pragmatic one at 291.6 nm and other at 346 nm. 291.6 nm was nominated as the wavelength for synchronized equation of MTZ and MHCl as it lies among the absorption maxima of both the drugs and hereafter it is adopted to be sensitive wavelength. Standard calibration curves for MTZ (Figure 1) and MHCl (Figure 2) were linear with correlation coefficients (r2) values in range of 0.9995–0.9999 at all the certain wavelengths and the values were average three impressions with standard deviation in the range of 0.001–0.014.

### Drug(s) Excipient Compatibility Studies

#### *Physical State*

The physical mixtures of drug and excipient(s) did not show any physical incompatibility in terms of discoloration, caking and liquefaction.

#### *FT-IR Spectroscopy*

The presence of excipient(s) did not result in any shift in the DRS of the drug(s) nor did it show the appearance of new peak (Figure 3). DRS Spectra of mixture of MTZ and MHCl along with polymers retained all the characteristic peaks of MTZ and MHCl and showed no incompatibility. Hence it can be concluded that periodontal films prepared by polymers

**Table 3:** Identification test

| *Identification Tests* | *Drug* | *Experimental value* | *Literature value* | *Remark* |
|---|---|---|---|---|
| Melting Point | Metronidazole | 160°C | 151–163°C | Purity indicated |
| | Minocycline HCl | 200°C | 200°C | Purity indicated |
| UV Spectrophotometric Study | Metronidazole (0.01 M hydrochloric acid 0.001% w/v drug solution) | 277 nm | 277 nm | indicated |
| | Minocycline HCl (0.01 M hydrochloric acid 0.001% w/v drug solution) | 275.5 nm | - | indicated |
| | Metronidazole (Phosphate buffer (pH=7.4)) | 319 nm | - | - |
| | Minocycline HCl (Phosphate buffer (pH=7.4)) | 273.8 nm | - | - |




**Figure 1:** Calibration curve of MTZ at 319nm, 273.8 nm 191.6 nm in phosphate buffer (pH 7.40)




**Figure 2:** Calibration of MHCl AT 319nm, 273.8 nm AND 191.6 nm in phosphate buffer pH 7.40

ethyl cellulose, hydroxyl propyl cellulose, hydroxyl propyl methylcellulose K4M (HPMC K4M), Eudragit L-100 and polymethyl methacrylate (PMMA 1, 20,000) are stable in terms of physical and chemical stability.

## Preparation of Drug(S) Loaded Fibers

The drug(s) loaded fibers were organized by coating practice. In order to coat extreme number of drug(s) on fibers, polymer and drug(s) solutions were systematized in ethanol and were diversified in diverse ratios (3:2, 1:1, 2:3 and 4:1). The fibers were coated five times. Consequently, each coating, the fiber was weighed to delineate the drug(s) load. The amount of drug(s) loaded was ancillary deep-rooted by quaking the fiber in ethanol and the substantial solution was filtered and analyzed spectrophotometrically by influential the absorbance at 319 nm and 273.8 nm and actual concentration of drug(s) was extrapolated from calibration curve of MTZ and MHCl organized at 319 nm and 273.8 nm. Coating was done five times and each time, the content of drug(s) extant in the coating was studied.

## Optimization of the Coating Solution

The augmented coating conformation prepared by solution practice was found to be one having 6 gm polymer solution and 4 gm drug(s) solution (Set A) (Table 1), while for method B (concentrated solution technique) it was combination of 5 gm polymer solution along with 5 gm drug(s) solution (Set G) (Table 2). As the amount of drug(s) in the solution amplified, amount of drug(s) merged in the coated fiber amplified. Hence extreme expanse of drug(s) could be fused into the fibers organized by using method B (concentrated solution technique).

## *In-vitro* Release of Drug(S) From Coated Fibers

Formulation A-I organized by solution technique (Method A), released 81.8% drug(s) over an epoch of 120 hours (Table 4); whereas G-II, prepared by concentrated solution practice (Method B), released 84% drug(s) over a period of 264 hours (Table 5). Existence of glycoproteins did not alter the $\lambda_{max}$ of the drug(s) analyzed by the UV method. It was bare that as the number of coatings improved, the percentage of drug(s) released dwindled because escalation in the number of polymer coats decreased diffusivity of the drug(s). Altered kinetic equations were pragmatic to interpret the release rate from the optimized fibre G-II at pH 6.6. The best fit with the utmost correlation was accomplished with the zero-order equation. When n approximates to 0.5, a Fickian/diffusion-controlled release is implied; when 0.5<n<10 a non-Fickian transport is implied; and when n = 1, zero-order release is designated. When values of n slant 1.0, one can clinch that release is forthcoming zero order. For the optimized formulation, value of n is 0.9314. The concentration of drug(s) in samples acquired from in situ release studies persisted well above the minimum inhibitory concentration value of the drug(s) over a period of 264 hours.

## Formulation's Optimization

The formulation was augmented on the center of percent drug(s) release over a period. Formulation A-II ('A' signposts the coating alignment including polymer solution and drug solution, i.e., 6 and 4 gm, discretely; and II postulates two coatings given to the fibers), controlled by solution technique (Method (A)), revealed determined drug release of 81.8% over a period of 120 hours (Table 4).




**Figure 3:** DRS spectra of (A) MHCl , MTZ and mixture, (B) HPMC, MTZ AND MHCl in combination, (C) Eudragit L-100, MTZ and MHCl in combination, (D) PMMA1, 20,000, MTZ and MHCl in combination, (E) HPC, MTZ AND MHCl in combination, (F) EC, MTZ and MHCl in combination

**Table 4:** Comparative *in-vitro* Release of drug(S) from the fibers prepared by solution technique (method A)

| *Formulation code* | *Maximum amount of drug(s) released n=3* | | *Time for maximum drug(s) release (hours)* |
|---|---|---|---|
| | *MTZ* | *MHCl* | |
| A-II | 81.8 (0.808) | 84.8 (0.907) | 120 |
| A-III | 55.12 (0.930) | 56.52 (0.587) | 120 |
| A-IV | 43.12 (1.071) | 41.12 (1.235) | 144 |
| A-V | 34.08 (1.071) | 30.08 (1.478) | 144 |
| B-II | 86.94 (1.189) | 81.94 (1.569) | 120 |
| B-III | 52.23 (0.707) | 50.23 (0.584) | 120 |
| B-IV | 46.42 (0.08) | 42.58 (0.07) | 120 |
| B-V | 43.16 (1.428) | 47.36 (1.541) | 144 |

**Table 5:** Comparative *in-vitro* Release of drug(S) from the fibers prepared by concentrated solution technique (method B)

| *Formulation code* | *Maximum amount of drug(s) release n=3 (+S.D.)* | | *Time for maximum drug(s) release (hours.)* |
|---|---|---|---|
| | *MTZ* | *MHCl* | |
| E-II | 87.14 (6.094) | 78.17 (6.094) | 144 |
| E-III | 83.34 (2.93) | 79.35 (2.93) | 216 |
| E-IV | 52.01 (3.336) | 57.55 (3.336) | 216 |
| E-V | 39.12 (2.619) | 42.23 (2.619) | 216 |
| F-II | 83.45 (3.763) | 84.45 (3.763) | 168 |
| F-III | 45.71 (1.421) | 45.48 (1.421) | 216 |
| F-IV | 49.54 (1.673) | 53.36 (1.673) | 216 |
| F-V | 39.47 (0.989) | 41.54 (0.989) | 216 |
| G-II | 84.08 (1.445) | 88.74 (1.445) | 264 |
| G-III | 51.02 (1.424) | 54.47 (1.424) | 240 |
| G-IV | 45.20 (0.457) | 47.32 (0.457) | 264 |
| G-V | 35.21 (1.747) | 31.69 (1.747) | 264 |
| H-II | 67.32 (0.823) | 65.54 (0.823) | 264 |
| H-III | 53.12 (2.860) | 57.89 (2.860) | 264 |
| H-IV | 36.07 (0.130) | 38.54 (0.130) | 288 |
| H-V | 30.35 (0.694) | 33.58 (0.694) | 240 |

However, formulation G-II postulates coating alignment comprehending 5 gm of drug solution (content of drug 100 mg) and 5 gm of polymer solution, and II signposts two coatings given to the fibers, prepared by method (B) released 84% drug over a period of 264 hours (11 days) (Table 5). Based on percent drug(s) release over a period of time, it was gritty that G-II was the augmented formulation. The augmented fiber of MTZ and MHCl (G-II) was appraised for broad advent. The color of the formulation was white with an exact irrelevant bitter taste. The fiber was slightly flexible in texture with a diameter of 0.6 mm and length of 10 cm.

## Microbiological Evaluation of *In-situ* Release Samples

*In situ* release study samples when tested against *S. aureus, S. mutans* and *B. cereus* exhibited that testers inhibited the advance of all the aforesaid microorganisms. The microbiological revision at one end publicized that the drug(s) released at innumerable time intervals was able to impede the evolution of microbes, although at the supplementary end, it also publicized that the drug(s) was firm to impede the growth of microbes even after 264 hours. Fiber without the drug(s) was also tested in contradiction of the aforesaid microorganisms and it was institute that the fiber without the drug(s) was not operative alongside the microorganisms

## Permeation Studies on the Optimized Fiber across Buccal Membrane

Permeation studies obliquely bovine cheek pouch membrane consuming reformed Franz diffusion cell disclosed that only 11.5% drug(s) infiltrated in 264 hours, portentous that truncated amount of drug(s) is predictable

to go into systemic circulation. The study broadcasted that the drug(s) in this formulation is released close by; henceforward it has a high assistance to risk ratio. Analysis of permeation rate data indicated that permeation monitored zero-order kinetics relatively than first order because coefficient of disparity was lower for zero-order (14.7) as concomitant to first-order (90.3).

## Conclusion

Periodontitis is often treated with a systemic regimen of antibiotics to eradicate the disease-causing bacteria. Some tetracycline's also appear to cause bone destruction by blocking collagenase. To ensure alveolar bone progress, an alternative technique is to surgically remove the pocket and raconteur the bone. For two reasons: to increase medication concentration directly at the site of action while also reducing systemic side effects such gastrointestinal problems, depression, and tachycardia, local administration into the periodontal pocket may be highly helpful Periodontal fibers carrying both drugs for prolonged release could be developed using this strategy. This technique allows for more time to be spent on the sick area, enhancing efficacy and compliance. The periodontal pocket fiber is peacefully engaged and confiscated. Local administration is preferred over systemic administration because of the higher help-to-risk ratio, which is unwanted due to the lower benefit-to-risk ratio. As a result, stumpy doses of site explicit fiber are preferable.

## References


1. Wang LC, Chen XG, Zhong DY, Xu QC. Study on poly(vinyl alcohol)/carboxymethyl-chitosan blend film as local drug delivery system. J Mater Sci Mater Med. 2007;18(6):1125-1133. doi: 10.1007/s10856-007-0159-5.
2. Agarwal RK, Robinson DH, Maze GI, Reinhardt RA. Development and characterization of tetracycline-poly (lactide/glycolide) films for the treatment of periodontitis. Journal of controlled release. 1993 Feb 1;23(2):137-146.
3. Webber WL, Mathiowitz E. Modulating tetracycline release from PLA/PG films. InProc. Int. Symp. Controlled Release Bioact. Mater 1997 ;24:575-576.
4. Maddiboyina B, Hanumanaik M, Nakkala RK, Jhawat V, Rawat P, Alam A, Foudah AI, Alrobaian MM, Shukla R, Singh S, Kesharwani P. Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension. Heliyon. 2020;6(11):e05459. doi: 10.1016/j.heliyon.2020.e05459.
5. Maddiboyina B, Desu PK, Vasam M, Challa VT, Surendra AV, Rao RS, Alagarsamy S, Jhawat V. An insight of nanogels as novel drug delivery system with potential hybrid nanogel applications. J Biomater Sci Polym Ed. 2021:1-17. doi: 10.1080/09205063.2021.1982643.
6. Bruschi ML, Jones DS, Panzeri H, Gremião MP, de Freitas O, Lara EH. Semisolid systems containing propolis for the treatment of periodontal disease: in vitro release kinetics, syringeability, rheological, textural, and mucoadhesive properties. J Pharm Sci. 2007;96(8):2074-2089. doi: 10.1002/jps.20843.
7. Maddiboyina B, Vikas J, Gandhi S, OmPrakash S, Ramya KN, Mudavath H, Monika G. Formulation Development and Characterization of Controlled Release Core in Cup Matrix Tablets of Venlafaxine HCl. Current Drug Therapy.2020; 15(5):503-511. Doi:org/10.2174/1574885515666200331104440
8. Polson AM, Stoller NH, Hanes PJ, Bandt CL, Garrett S, Southard GL. 2 multi-center trials assessing the clinical efficacy of 5% sanguinarine in a biodegradable drug delivery system. J Clin Periodontol. 1996;23(8):782-788. doi: 10.1111/j.1600-051x.1996.tb00610.x.
9. Noyan U, Yilmaz S, Kuru B, Kadir T, Acar O, Büget E. A clinical and microbiological evaluation of systemic and local metronidazole delivery in adult periodontitis patients. J Clin Periodontol. 1997;24(3):158-165. doi: 10.1111/j.1600-051x.1997.tb00485.x..
10. Maze GI, Reinhardt RA, Payne JB, Maze C, Baker RA, Bouwsma OJ, Damani NC, Fitzgerald J, Hamlin JC, Gerlach RW. Gingival fluid tetracycline release from bioerodible gels. J Clin Periodontol. 1996;23(12):1133-1136. doi: 10.1111/j.1600-051x.1996.tb01815.x..
11. Maddiboyina B, Jhawat V, Desu PK, Gandhi S, Nakkala RK, Singh S. Formulation and evaluation of thermosensitive flurbiprofen in situ nano gel for the ocular delivery. J Biomater Sci Polym Ed. 2021;32(12):1584-1597. doi: 10.1080/09205063.2021.1927460.
12. Esposito E, Cortesi R, Cervellati F, Menegatti E, Nastruzzi C. Biodegradable microparticles for sustained delivery of tetracycline to the periodontal pocket: formulatory and drug release studies. J Microencapsul. 1997;14(2):175-187. doi: 10.3109/02652049709015331.
13. Jeyanthi R, Akiyama A, Roberts FD, VanHamont J, Friden P. One-month controlled release of an antimicrobial peptide from biodegradable poly (lactide/glycolide) microspheres for the treatment of periodontitis. InProceedings of 24th International Symposium Controlled Release Bioactive Mater 1997 Jun, 883-884.
14. Mundargi RC, Srirangarajan S, Agnihotri SA, Patil SA, Ravindra S, Setty SB, Aminabhavi TM. Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies. J Control Release. 2007;119(1):59-68. doi: 10.1016/j.jconrel.2007.01.008.
15. Kong LX, Peng Z, Li SD, Bartold PM. Nanotechnology and its role in the management of periodontal diseases. Periodontol 2000. 2006;40:184-96. doi: 10.1111/j.1600-0757.2005.00143.x.
16. Maddiboyina B, Asthana A, Asthana GS, Singh S, Ramya KN, Sunnapu O, Kotla N. Formulation and Characterization of Polycarbophil Coated Mucoadhesive Microspheres of Repaglinide. J Pharma Sci and Res. 2015;7 (11):972-977.
17. Sood S, Maddiboyina B, Rawat P, Garg AK, Foudah AI, Alam A, Aldawsari HM, Riadi Y, Singh S, Kesharwani P. Enhancing the solubility of nitazoxanide with solid dispersions technique: formulation, evaluation, and cytotoxicity study. J Biomater Sci Polym Ed. 2021;32(4):477-487. doi: 10.1080/09205063.2020.1844506.


**How to Cite this Article:** Kumar KV, Sasidhar RLC, Deepthi B. Formulation, Formulation Development and Evaluation of Site Specific Periodontal Fibers of Metronidazole and Minocycline HCl. Int. J. Pharm. Sci. Drug Res. 2021;13(6):638-645. DOI: 10.25004/IJPSDR.2021.130606